Clinical Trial Search

Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035

Primary: Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery (CR/CRh*) During the First Two Treatment Cycles — 35.6…

Primary: Response Rate (RR) — 11 Participants

Primary: Phase 1b: Number of Participants With Dose-limiting Toxicities — 0; 0 Participants

Primary: Response Rate — 0.846; 0.786; 0.154; 0.214 proportion of participants

Primary: Occurrence of a Dose-Limiting Toxicity (Phase 1) — 0; 1; 4; 5 Participants

Primary: Kaplan Meier Estimate: Event-Free Survival (EFS; Primary Analysis) — 7.4; NA months — p=< 0.001

Primary: Best Overall Response Rate (ORR) — 6; 0; 1; 0 Participants

Primary: Percentage of Participants With a Hematological Response of Complete Remission (CR) or Complete Remission With Partial Hematological Recovery (CRh*) During the First 2…

Primary: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment — 42.9…

Primary: Remission Re-induction (CR2) Rate — .646; .660 proportion of participants

Primary: Complete Response (CR or CRi) — 0 proportion of participants

Primary: The Primary End-point is the Number of Patients in CR After Induction Therapy. — 9 Participants

Primary: Phase I: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 1; 2; 1 participants

Primary: 3-Year Event-Free Survival (EFS) — 68 Participants

Primary: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment — 71.4…

Primary: Complete Remission — 52 percentage of participants

Primary: Number of Patients With Complete Remission — 3 participants

Primary: The Dose of AC220 That is Safe and Biologically Active When Given in Sequential Combination With Ara-C/Etoposide — 0; 3; 1; 4 Participants

Primary: Phase I: Incidence of Any DLT Attributed to DT2219 in the First Cycle — 1; 3; 0 events

Primary: Achievability of Performing Individualized Drug Screening and Initiating Therapy Based on the Results of the Drug Screen for Poor Risk Patients With Relapsed or…

Primary: Determination of the Maximum Tolerated Dose (MTD) of BI 836858 — NA; NA Milligram (mg)

Primary: Frequency of Dose Limiting Toxicities of Palbociclib — 1; 0 Participants

Primary: Response Rate — 0; 0; 0 participants

Primary: Overall Complete Remission Rate at Day 28 After CART-19 Therapy — 8; 10; 6; 6 Participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 69 Participants

Primary: MTD of VSLI — 2.25 mg/m2

Primary: Phase 1: Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0 percentage of participants

Primary: Number of Participants Who Achieved a Morphologic Complete Response Within the First Four Cycles of Lenalidomide Treatment According to the Modified International…

Primary: DFS of Non-DS HR Post-induction Patients Receiving Intrathecal (IT) Methotrexate (MTX) Compared With Patients Receiving Intrathecal Triple Therapy (ITT) on a Modified…